These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

439 related items for PubMed ID: 9660721

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Calretinin, thrombomodulin, CEA, and CD15: a useful combination of immunohistochemical markers for differentiating pleural epithelial mesothelioma from peripheral pulmonary adenocarcinoma.
    Comin CE, Novelli L, Boddi V, Paglierani M, Dini S.
    Hum Pathol; 2001 May; 32(5):529-36. PubMed ID: 11381372
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. "Thick" cell membranes revealed by immunocytochemical staining: a clue to the diagnosis of mesothelioma.
    Leong AS, Parkinson R, Milios J.
    Diagn Cytopathol; 1990 May; 6(1):9-13. PubMed ID: 2323301
    [Abstract] [Full Text] [Related]

  • 9. The use of the monoclonal antibody mesothelin in the diagnosis of malignant mesothelioma in pleural biopsies.
    Galloway ML, Murray D, Moffat DF.
    Histopathology; 2006 May; 48(6):767-9. PubMed ID: 16681698
    [No Abstract] [Full Text] [Related]

  • 10. Malignant mesothelioma: immunohistochemistry and DNA ploidy analysis as methods to differentiate mesothelioma from benign reactive mesothelial cell proliferation and adenocarcinoma in pleural and peritoneal effusions.
    Friedman MT, Gentile P, Tarectecan A, Fuchs A.
    Arch Pathol Lab Med; 1996 Oct; 120(10):959-66. PubMed ID: 12046609
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. [Malignant mesothelioma of the pleura. Analysis of its immunohistochemical aspects].
    Chenard-Neu MP, Bellocq JP, Maier A, Batzenschlager A.
    Ann Pathol; 1990 Oct; 10(1):20-7. PubMed ID: 2328062
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. E-cadherin, E-selectin and vascular cell adhesion molecule: immunohistochemical markers for differentiation between mesothelioma and metastatic pulmonary adenocarcinoma?
    Müller AM, Weichert A, Müller KM.
    Virchows Arch; 2002 Jul; 441(1):41-6. PubMed ID: 12111199
    [Abstract] [Full Text] [Related]

  • 17. The diagnostic utility of D2-40 for malignant mesothelioma versus pulmonary carcinoma with pleural involvement.
    Saad RS, Lindner JL, Lin X, Liu YL, Silverman JF.
    Diagn Cytopathol; 2006 Dec; 34(12):801-6. PubMed ID: 17115439
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. The value of calretinin and cytokeratin 5/6 as markers for mesothelioma in cell block preparations of serous effusions.
    Shield PW, Koivurinne K.
    Cytopathology; 2008 Aug; 19(4):218-23. PubMed ID: 17916095
    [Abstract] [Full Text] [Related]

  • 20. Carcinoembryonic antigen and milk-fat globule protein staining of malignant mesothelioma and adenocarcinoma of the lung.
    Tron V, Wright JL, Churg A.
    Arch Pathol Lab Med; 1987 Mar; 111(3):291-3. PubMed ID: 2435259
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.